CurrentCapital BluecrossPolicy MP 4.033

Diagnosis and Treatment of Dry Eye Syndrome

Defines Capital BlueCross coverage stance for eyelid thermal pulsation, intense pulsed light (IPL), and near‑infrared meibography for management and diagnosis of dry eye syndrome (meibomian gland dysfunction) for affected plan members.

Policy Summary

PayerCapital Bluecross

PolicyDiagnosis and Treatment of Dry Eye Syndrome

Policy CodePolicy MP 4.033

Change TypeNo material changes

Effective DateFeb 1, 2026

Next Review Date

Key ActionVerify member benefit and prior authorization because eyelid thermal pulsation, IPL, and near‑infrared meibography are considered investigational and may be denied.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

13trials in 2024 Cochrane meta-analysis

10trials in 2022 review

≥5FDA-cleared systems

Investigationalprocedure codes

MP 4.033policy id

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations

Coverage stance for eyelid thermal pulsation, IPL, and near‑infrared meibography

Policy conclusions based on current evidence:

Investigational — eyelid thermal pulsation and IPL: Eyelid thermal pulsation therapy and intense pulsed light (IPL) with subsequent meibomian gland expression are considered investigational for management of Dry Eye Syndrome due to insufficient evidence of net health benefit.

Supported by policy statement and evidence summaries.

Investigational — near‑infrared dual imaging: Near-infrared dual imaging of the Meibomian glands is considered investigational due to insufficient evidence of benefit.

Policy explicitly lists this imaging modality as investigational.

General coverage conclusion

Coverage stance summary based on available evidence

Overall evidence conclusion: The evidence is insufficient to determine that these technologies result in an improvement in the net health outcome; therefore certain device-based therapies and related imaging are considered investigational and not covered.

Based on systematic reviews, RCTs with limitations, and need for additional high-quality trials; investigational procedure codes are listed as not covered.

The policy explicitly names the following modalities as investigational for management of Dry Eye Syndrome: eyelid thermal pulsation therapy (device-based eyelid heating with pulsatile expression) and intense pulsed light (IPL) with subsequent meibomian gland expression. Near‑infrared dual imaging of the Meibomian glands (high‑definition meibography) is also listed as investigational. These specific therapies and imaging modalities are excluded from coverage for the stated indications because current evidence is insufficient to support net health benefit.

Procedures and associated billing codes that are identified in the policy as investigational are excluded from coverage. The policy lists investigational procedure codes including 0207T, 0330T, 0507T, and 0563T; services billed using these codes for the investigational indications may be denied.

After review of randomized trials, systematic reviews, and observational studies, the policy concludes that the evidence is insufficient to determine that these technologies improve net health outcome. A 2024 Cochrane meta-analysis and other evidence sources found mixed results and limitations in study quality; therefore device‑based eyelid treatments and near‑infrared meibography are considered investigational pending higher‑quality data.

Because the body of evidence does not establish a clear clinical benefit, the policy states that these investigational procedures are not medically necessary for coverage purposes. Thermal pulsation systems and related device‑based eyelid procedures identified as investigational are not covered under this policy and may be denied when billed.

Related Procedure and Billing Codes

Regulatory/Product Codesmixed

FDA product code ORZ

Eyelid thermal pulsation systems (LipiFlow and similar)

Investigational, therefore not coveredCPTNot Covered

0207T	Investigational procedure code (listed)
0330T	Procedure code listed as investigational
0507T	Procedure code listed as investigational
0563T	Procedure code listed as investigational

Provider Responsibilities and Authorization Guidance

Prior Authorization

Prior Authorization Required

Prior authorization is required for eyelid thermal pulsation therapy (e.g., LipiFlow®, iLux®, TearCare®) and intense pulsed light (IPL) procedures when the member’s benefit plan requires it. Verify member eligibility, benefits, and any prior authorization requirements with Capital BlueCross before scheduling.

Affected devices: LipiFlow®, iLux®, Systane® iLux2®, TearCare® systems.
Check for plan-specific PA requirements and medical necessity criteria prior to service.

Denial Risk

Investigational — Denial Risk

These procedures are considered investigational for treatment of Dry Eye Syndrome under this policy and may be denied if billed. Claims for investigational procedures (including eyelid thermal pulsation and IPL) should be supported by documentation if submitted for review.

Clinical Background

Meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye and is characterized by obstructed or dysfunctional meibomian glands that impair the lipid layer of the tear film. Device‑based thermal pulsation systems deliver localized heat to the eyelids combined with pulsatile pressure to express gland contents; IPL delivers broad‑spectrum light (commonly described in the literature as wavelengths roughly spanning 550–1200 nm) over the eyelids and is frequently followed by manual gland expression. Although these procedures are intended to improve gland function and tear film stability, current evidence is judged insufficient to demonstrate improved patient‑level outcomes, and the policy therefore considers them investigational.

Definitions and Device Descriptions

inv-18: Thermal pulsation therapy (e.g., LipiFlow, iLux, TearCare)

DefinitionDevice-based therapy delivering localized heat and pulsatile pressure to the eyelids to express obstructed Meibomian glands (examples: LipiFlow, iLux, TearCare).

Intended effectHeat plus graded pulsatile pressure applied to palpebral surfaces to liquefy and express meibomian gland contents, improving tear film stability for MGD-related dry eye.

Regulatory status noteSeveral eyelid thermal pulsation systems (e.g., LipiFlow) are FDA-cleared products, but clinical benefit evidence is limited in certainty.

Evidence summarySystematic reviews and RCTs report improvements in some outcomes (e.g., TBUT), but evidence quality is low to very low and longer, well-masked trials are needed.

Clinical contextConsidered a step‑2 therapy in guidelines after inadequate response to conservative measures (lid hygiene, warm compresses, lubricants).

Policy Revision History

2025-06-16consensus reviewLatest

Consensus review; no change to policy statement; cross-referenced policies, background, and rationale updated; references added.

2024-06-20consensus review

Consensus review; no changes to policy statement; background and references updated; coding reviewed with no changes.

2023-05-26consensus review

Policy Summary

PayerCapital Bluecross

PolicyDiagnosis and Treatment of Dry Eye Syndrome

Policy CodePolicy MP 4.033

Change TypeNo material changes

Effective DateFeb 1, 2026

Next Review Date

Key ActionVerify member benefit and prior authorization because eyelid thermal pulsation, IPL, and near‑infrared meibography are considered investigational and may be denied.

SourceLink

On This Page

Investigational / not covered codes (examples listed in policy): 0207T, 0330T, 0507T, 0563T.

Presence of investigational status may result in claim denial or delay.

Step Therapy

Step Therapy and Conservative Treatment Documentation

Document that the member has completed an adequate trial of conservative (step 1) therapies and that these were inadequate prior to considering step 2 options per AAO guidance. Include dates, duration, and response to therapy in the medical record.

Conservative therapies (step 1): lid hygiene, dietary/environmental modification, removal of offending agents, patient education, ocular lubricants.
Document trial length and objective/subjective treatment response before escalation.

Documentation Required

Benefit and Medical Necessity Verification

Confirm and document medical necessity criteria and benefit coverage before performing or billing for thermal pulsation/IPL. Maintain clinical records showing prior conservative therapy, reason for escalation, and device used. Contact Provider Services for coverage questions.

Verify benefit plan, eligibility, and medical necessity on date of service.
Retain documentation of prior therapies and clinical justification for step‑up treatment.

Billing Rule

Investigational Procedure Coding and Denial Risk

Coding in the policy lists investigational procedure codes that may be denied when billed. Use correct and current CPT/HCPCS coding and include supportive documentation if pursuing prior authorization or appeal.

Policy coding note: listed codes do not guarantee coverage; coverage depends on member benefits.
If submitting for review, include clinical records demonstrating prior conservative therapy and rationale for the procedure.

inv-19: Intense pulsed light (IPL)

DefinitionProcedure emitting broad-spectrum light (approximately 550–1200 nm) applied to the eyelids, frequently followed by manual meibomian gland expression.

Proposed mechanismWarming of eyelid tissues and modulation of periocular inflammation thought to facilitate expression of gland contents.

Evidence summarySystematic reviews and clinical studies report mixed results; quality of evidence is variable and insufficient to confirm net health benefit.

Clinical roleInvestigated as a step‑2 option for MGD-related dry eye when conservative therapies are inadequate.

inv-20: Near‑infrared dual imaging (high‑definition meibography)

DefinitionImaging technique using transillumination and near-infrared technology to capture high‑definition images of Meibomian glands (e.g., LipiScan/LipiView).

Use casesUsed for screening, documentation of gland morphology, and potential surgical planning or monitoring of MGD.

LimitationsPolicy lists near‑infrared dual imaging as investigational due to insufficient evidence of clinical benefit for management decisions.

inv-21: Thermal pulsation (alternate inventory entry)

Alternate termThermal pulsation (device-based eyelid heating with pulsatile expression; examples include LipiFlow, TearCare).

MechanicsApplies controlled heat to palpebral surfaces and graded pulsatile pressure to express obstructed glands while monitoring temperature and pressure.

Evidence noteRCTs show some improvements (e.g., TBUT) but overall evidence is low certainty; additional high-quality trials with longer follow-up are needed.

Coverage stancePolicy considers thermal pulsation investigational and not medically necessary for treatment of dry eye syndrome under this policy.

inv-22: Intense pulsed light (IPL) — alternate inventory entry

Alternate termIntense pulsed light (IPL) — light-based eyelid therapy often combined with meibomian gland expression.

WavelengthsTypical IPL energy applied spans approximately 550–1200 nm (broad-spectrum), per clinical descriptions.

Evidence & policy stanceClinical studies exist but evidence is insufficient; IPL is considered investigational and not covered per policy.

Coding cautionCertain procedure codes related to IPL and device-based eyelid procedures are listed as investigational and may be denied.

Consensus review; no changes to policy statement; background, rationale, and references updated.

2022-03-25minor review

Minor review that changed eyelid thermal pulsation therapy or IPL to not medically necessary and updated background and references.